HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations., Hea ...

New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically ...

Why is AIDS a syndrome and not a disease? What is syndrome?Lookman (by SMS) AIDS is the result of untreated HIV (Human Immunodeficiency Virus). Over time, HIV destroys CD4-T white blood cells, ...

Long-Term Outcomes Reinforce the High Efficacy of Biktarvy ® in People with HIV and HBV Coinfection – – Investigational Long-Acting, Twice-Yearly Treatment Regimen of Len ...

In HIV-positive MSM, pain severity was significantly associated with pain management experiences and unhealthy alcohol use.

The presence of anti-CD4 autoantibodies in treatment-naive patients with advanced HIV was associated with a decreased rate of CD4 reconstitution following ART initiation.

SAN FRANCISCO -- Most patients with HIV who received two broadly neutralizing antibodies (bNAbs) after pausing antiretroviral ...

Research on the presence of thyroid abnormalities in HIV showed that patients with HIV are at risk for developing a variety of thyroid disorders.

A research team from the Medical University of Vienna has made further progress in the treatment of intestinal inflammation.